Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
samatasvir + simeprevir + ribavirin
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy of **samatasvir** (IDX719), **simeprevir** (TMC435), and **ribavirin** is an investigational, all-oral, direct-acting antiviral regimen studied for the treatment of chronic hepatitis C virus (HCV) infection. - **Samatasvir** is an NS5A inhibitor targeting HCV replication complex. - **Simeprevir** is an NS3/4A protease inhibitor that blocks viral protein processing, preventing HCV maturation[2][4][5]. - **Ribavirin** is a nucleoside analog with broad-spectrum antiviral activity, generally used in combination with other agents to enhance efficacy. This combination was evaluated in clinical trials (not approved for marketing) for safety, tolerability, efficacy, and pharmacokinetics in treatment-naïve adults with HCV genotypes 1b, 4, and 6, sometimes with additional antivirals. The regimen aimed to provide potent, interferon-free treatment for chronic HCV infection with the goal of achieving a sustained virologic response[3][6][8].
- Other names
- samatasvir + simeprevir + RBV
02
Targets
NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))
Beyond the preview
Go deeper on samatasvir + simeprevir + ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on samatasvir + simeprevir + ribavirin.